Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

EmVenio Research Inc

Neither a doctor nor a teaching hospital

Research payments

$2,159,423

147 payments

Through program year 2025, EmVenio Research Inc is reported as receiving $2,159,423 in research payments, across 147 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,519,095 136
2024 Research $626,328 10
2023 Research $14,000 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,467,196 82 payments
  2. Moderna TX, Inc. $576,393 54 payments
  3. Novavax Inc $53,391 7 payments
  4. Pfizer Inc. $47,242 3 payments
  5. Sanofi US Services Inc. $15,200 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $576,393 54 payments
  2. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $537,621 44 payments
  3. Phase III efficacy for obesity - without T2DM $344,726 2 payments
  4. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus $342,639 34 payments
  5. phase III efficacy for obesity - with T2DM $242,211 2 payments
  6. A Phase 2B Multicenter Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Onceweekly Met097 in Adults With Obesity Or Overweight and Type 2 Diabetes Mellitus Vesper2 $47,242 3 payments
  7. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants $39,391 6 payments
  8. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $15,200 1 payment
  9. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naive Participants $14,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record